TNSN04200A1 - Peptides et leur application en therapeutique - Google Patents

Peptides et leur application en therapeutique

Info

Publication number
TNSN04200A1
TNSN04200A1 TNP2004000200A TNSN04200A TNSN04200A1 TN SN04200 A1 TNSN04200 A1 TN SN04200A1 TN P2004000200 A TNP2004000200 A TN P2004000200A TN SN04200 A TNSN04200 A TN SN04200A TN SN04200 A1 TNSN04200 A1 TN SN04200A1
Authority
TN
Tunisia
Prior art keywords
moins
peptide
composé
une
immunogène
Prior art date
Application number
TNP2004000200A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Jean-François ZAGURY
Original Assignee
Vaxconsulting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxconsulting filed Critical Vaxconsulting
Publication of TNSN04200A1 publication Critical patent/TNSN04200A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TNP2004000200A 2002-04-10 2004-10-08 Peptides et leur application en therapeutique TNSN04200A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204464A FR2838444B1 (fr) 2002-04-10 2002-04-10 Nouveaux peptides et leur application en therapeutique
PCT/FR2003/001120 WO2003084979A2 (fr) 2002-04-10 2003-04-09 Peptides et leur application en therapeutique

Publications (1)

Publication Number Publication Date
TNSN04200A1 true TNSN04200A1 (fr) 2007-03-12

Family

ID=28459716

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000200A TNSN04200A1 (fr) 2002-04-10 2004-10-08 Peptides et leur application en therapeutique

Country Status (20)

Country Link
US (6) US7393523B2 (enExample)
EP (3) EP2314311B1 (enExample)
JP (1) JP2005530723A (enExample)
KR (1) KR101101004B1 (enExample)
CN (1) CN1649898A (enExample)
AT (1) ATE526985T1 (enExample)
AU (1) AU2003260031B2 (enExample)
CA (1) CA2480996C (enExample)
DK (1) DK2314311T3 (enExample)
ES (2) ES2375053T3 (enExample)
FR (1) FR2838444B1 (enExample)
IL (1) IL164429A0 (enExample)
MA (1) MA27191A1 (enExample)
MX (1) MXPA04009841A (enExample)
NZ (1) NZ536351A (enExample)
RU (1) RU2326125C2 (enExample)
SI (1) SI2314311T1 (enExample)
TN (1) TNSN04200A1 (enExample)
WO (1) WO2003084979A2 (enExample)
ZA (1) ZA200408451B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
US7892558B2 (en) 2004-02-27 2011-02-22 Vaxconsulting Isolated TNF-alpha peptide and pharmaceutical composition thereof
KR20080047564A (ko) 2005-09-28 2008-05-29 사이토스 바이오테크놀로지 아게 인터루킨-1 컨쥬게이트 및 그의 용도
ES2620437T3 (es) * 2008-11-17 2017-06-28 Københavns Universitet Péptidos derivados de IL-4 para la modulación de la respuesta inflamatoria crónica y el tratamiento de enfermedades autoinmunes
US9301997B2 (en) 2009-09-21 2016-04-05 Peptinov Sas Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
ES2602436T3 (es) 2010-05-11 2017-02-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Inhibidor basado en péptido de la activación de interleucina 10 o STAT-3
CN110133298A (zh) * 2012-03-18 2019-08-16 株式会社资生堂 疾病样品分析装置、分析系统及分析方法
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
JP2018521016A (ja) * 2015-06-03 2018-08-02 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ ＩＬ−２３−ｐ１９ワクチン
US11760792B2 (en) * 2017-10-13 2023-09-19 Nibec Co., Ltd. GRP78-derived peptide for identifying high-efficiency stem cells
CU20210092A7 (es) * 2019-05-10 2022-06-06 Bimyo GmbH Péptidos bnip3 para el tratamiento de la lesión por reperfusión
EP4486387A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate consisting of or comprising at least a ss-glucan or a mannan

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
DE3841761A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
CZ283050B6 (cs) * 1989-12-20 1997-12-17 Schering Corporation Polypeptid, jeho subsekvence a jejich použití
EP0521918A4 (en) * 1990-03-19 1993-05-05 Peptide Technology Ltd Anti-tumour peptides
FR2677654B1 (fr) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
US6117974A (en) * 1991-10-02 2000-09-12 Peptor Limited Libraries of backbone-cyclized peptidomimetics
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
CA2139571C (en) * 1992-07-07 2006-11-14 Eleanor N. Fish Interferon receptor binding peptides
US5770191A (en) * 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
IT1277926B1 (it) * 1995-09-01 1997-11-12 Angeletti P Ist Richerche Bio Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
EP1005354A4 (en) * 1997-02-07 2002-05-15 Univ Jefferson PEPTIDE MIMETICS OF THE GAMMA CHAIN OF CYTOKINE RECEPTORS
IT1291353B1 (it) * 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
WO1999050416A1 (en) * 1997-09-30 1999-10-07 Pharmacia & Upjohn Company Tnf-related death ligand
NZ513507A (en) * 1999-02-08 2003-08-29 Medvet Science Pty Ltd Cytokine-binding domain
KR20010102556A (ko) * 1999-03-11 2001-11-15 추후제출 암 및 과증식성 장애의 치료 조성물 및 치료방법
US7129072B1 (en) * 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US6420346B1 (en) * 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
US20030166589A1 (en) * 2001-06-05 2003-09-04 Nathan Karin Method and pharmaceutical composition for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
US7641895B2 (en) 2010-01-05
EP2314312A2 (fr) 2011-04-27
WO2003084979A2 (fr) 2003-10-16
EP1492814B1 (fr) 2011-10-05
CN1649898A (zh) 2005-08-03
RU2004132871A (ru) 2005-09-20
EP2314311B1 (fr) 2015-07-15
US20120321652A1 (en) 2012-12-20
SI2314311T1 (sl) 2015-12-31
US7393523B2 (en) 2008-07-01
ATE526985T1 (de) 2011-10-15
MXPA04009841A (es) 2005-06-17
ES2550030T3 (es) 2015-11-04
KR20040108709A (ko) 2004-12-24
FR2838444A1 (fr) 2003-10-17
RU2326125C2 (ru) 2008-06-10
WO2003084979A3 (fr) 2004-04-08
DK2314311T3 (en) 2015-10-12
CA2480996A1 (fr) 2003-10-16
US8147819B2 (en) 2012-04-03
KR101101004B1 (ko) 2011-12-29
FR2838444B1 (fr) 2016-01-01
MA27191A1 (fr) 2005-01-03
EP2314311A2 (fr) 2011-04-27
EP1492814A2 (fr) 2005-01-05
IL164429A0 (en) 2005-12-18
JP2005530723A (ja) 2005-10-13
AU2003260031B2 (en) 2009-10-29
AU2003260031A1 (en) 2003-10-20
US20060241286A1 (en) 2006-10-26
ZA200408451B (en) 2006-01-25
EP2314311A3 (fr) 2011-08-17
US20080260689A1 (en) 2008-10-23
US20110171169A1 (en) 2011-07-14
ES2375053T3 (es) 2012-02-24
US20100150957A1 (en) 2010-06-17
EP2314312A3 (fr) 2011-08-31
US7892529B2 (en) 2011-02-22
CA2480996C (fr) 2016-06-21
US8529881B2 (en) 2013-09-10
US20120121627A1 (en) 2012-05-17
US8277792B2 (en) 2012-10-02
NZ536351A (en) 2007-03-30

Similar Documents

Publication Publication Date Title
TNSN04200A1 (fr) Peptides et leur application en therapeutique
Paul et al. Secukinumab improves hand, foot and nail lesions in moderate‐to‐severe plaque psoriasis: subanalysis of a randomized, double‐blind, placebo‐controlled, regimen‐finding phase 2 trial
Pasco et al. Clinical implications of the cytokine hypothesis of depression
Rousseau et al. Effect of combined androgen blockade with an LHRH agonist and flutamide in one severe case of male exhibitionism
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
WO2003103585A3 (en) Methods of treating angiogenesis, tumor growth, and metastasis
YU12097A (en) 6-phenilpyridyl-2-amine derivatives
EA200801071A1 (ru) Способы и композиции для применения в целях лечения пациентов с положительным по аутоантителам заболеванием
EA200500583A1 (ru) Ингибиторы белка-регулятора трансмембранной проводимости при муковисцидозе и их применение
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
ATE433954T1 (de) Hydroxamate als therapeutische mittel
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
MA26955A1 (fr) INHIBITEURS DES RECEPTEURS EP4 POUR LE TRAITEMENT DE L'ARTHRITE RHUMATOiDE
MA27443A1 (fr) Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
EA200500782A1 (ru) Лечение геморрагического шока
Callan et al. Multiple papillomavirus‐associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
ES2155093T3 (es) Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa).
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EE9900275A (et) CD40L-vastaste ühendite terapeutilise manustamise meetodid
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
Tsai et al. Regulation of interleukin‐6 expression by arecoline in human buccal mucosal fibroblasts is related to intracellular glutathione levels